Compare stocks

ALK-Abelló A/S is a pharmaceutical company engaged in the development and production of allergy immunotherapy products. Based in Hørsholm, Denmark, the company specializes in allergy treatments that include tablets, injections, and drops targeting common allergens such as grass, tree, and ragweed pollen, as well as house dust mites. Established in the early 20th century, ALK-Abelló has expanded its operations to serve markets globally, with a particular focus on Europe and North America. Its strategic advantage lies in its strong research capabilities and a comprehensive portfolio of allergy treatment options. The company's ongoing investment in innovation supports its goal to transform the treatment of allergies worldwide.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.